LUX-Lung: determining the best EGFR inhibitor in NSCLC?
- 1 February 2015
- journal article
- editorial
- Published by Elsevier in The Lancet Oncology
- Vol. 16 (2) , 118-119
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsThe Lancet Oncology, 2015
- Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-AnalysisJNCI: Journal of the National Cancer Institute, 2013
- Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancerLung Cancer, 2013
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR MutationsJournal of Thoracic Oncology, 2012
- EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992Targeted Oncology, 2010
- Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or ErlotinibClinical Cancer Research, 2006
- The Challenge of Subgroup Analyses — Reporting without DistortingNew England Journal of Medicine, 2006
- Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or ErlotinibClinical Cancer Research, 2006
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004